(EYPT) Eyepoint Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30233G2093
EYPT: Retinal, Disease, Treatment, Delivery, Inhibitor, Agonist
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for serious retinal diseases. The companys proprietary Durasert E technology enables sustained intraocular drug delivery, addressing the limitations of traditional treatments that require frequent injections. This bioerodible platform is designed to improve patient outcomes by maintaining therapeutic drug levels over extended periods.
The companys lead product candidate, EYP-1901, combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert E delivery system. Currently in Phase 2 clinical trials, EYP-1901 targets VEGF-mediated retinal diseases, including wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). Vorolanibs mechanism of action inhibits multiple kinases involved in angiogenesis and inflammation, potentially offering a broader therapeutic effect compared to existing treatments.
Eyepoints pipeline also includes EYP-2301, a TIE-2 agonist formulated with Durasert E. TIE-2 agonists have shown promise in stabilizing vasculature and reducing inflammation, making EYP-2301 a potential candidate for addressing retinal diseases characterized by pathological neovascularization and vascular leakage. The companys focus on combination therapies and its proprietary delivery platform positions it as a key player in the ophthalmology sector.
Founded in 1987 as pSivida Corp., the company rebranded as Eyepoint Pharmaceuticals, Inc. in March 2018 to reflect its expanded focus on retinal diseases. Headquartered in Watertown, Massachusetts, Eyepoint has established itself as a leader in intraocular drug delivery systems, with a strong intellectual property portfolio and a commitment to advancing sight-saving therapies.
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals
Last Price: 6.23
SMA 20: 6.63
SMA 50: 7.35
SMA 200: 8.91
ATR: 0.65
P/E: 0.00
P/E Forward: 0.00
P/B: 1.97
P/S: 9.70
RoE: -47.35
3-Month Forecast:
Based on the technical data, EYPTs short-term outlook appears bearish, with the SMA 20 and SMA 50 trending downward, indicating potential weakness in the stock price. The ATR of 0.65 suggests moderate volatility, while the average volume of 967,555 shares indicates liquidity. The fundamental data shows a negative RoE of -47.35, reflecting ongoing losses, but the P/B ratio of 1.97 suggests the market values the companys assets near book value. The forward P/E remains undefined, highlighting the speculative nature of the stock. Over the next 3 months, EYPT is likely to face downward pressure due to technical resistance and lack of near-term catalysts, but the companys pipeline progress could act as a counterbalance.
Additional Sources for EYPT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EYPT Stock Overview
Market Cap in USD | 448m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2005-01-27 |
EYPT Stock Ratings
Growth 5y | -27.5% |
Fundamental | -45.8% |
Dividend | 0.0% |
Rel. Strength Industry | -70.3 |
Analysts | 4.67/5 |
Fair Price Momentum | 5.26 USD |
Fair Price DCF | - |
EYPT Dividends
No Dividends PaidEYPT Growth Ratios
Growth Correlation 3m | -60.9% |
Growth Correlation 12m | -77.9% |
Growth Correlation 5y | 9.6% |
CAGR 5y | -6.85% |
CAGR/Max DD 5y | -0.08 |
Sharpe Ratio 12m | -1.77 |
Alpha | -79.38 |
Beta | 0.80 |
Volatility | 84.51% |
Current Volume | 983.2k |
Average Volume 20d | 776.1k |
As of March 15, 2025, the stock is trading at USD 6.52 with a total of 983,246 shares traded.
Over the past week, the price has changed by -8.56%, over one month by +0.31%, over three months by -14.32% and over the past year by -70.01%.
Probably not. Based on ValueRay Fundamental Analyses, Eyepoint Pharmaceuticals (NASDAQ:EYPT) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -45.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EYPT as of March 2025 is 5.26. This means that EYPT is currently overvalued and has a potential downside of -19.33%.
Eyepoint Pharmaceuticals has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy EYPT.
- Strong Buy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, EYPT Eyepoint Pharmaceuticals will be worth about 5.8 in March 2026. The stock is currently trading at 6.52. This means that the stock has a potential downside of -11.35%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 33 | 406.1% |
Analysts Target Price | 33.4 | 412.6% |
ValueRay Target Price | 5.8 | -11.3% |